Introduction
Despite efforts to reduce lung cancer mortality with surgery, radiation therapy or chemotherapy, lung cancer is the leading cause of cancer death in the United States. Chemoprevention, which aims at preventing, inhibiting or reversing carcinogenesis (Sporn et al., 1976) , is an attractive strategy to limit the clinical impact of lung cancer. The retinoids, natural and synthetic derivatives of vitamin A, have a role in cancer chemoprevention based on preclinical studies, epidemiological evidence and initial clinical trials treating premalignacies or preventing second malignancies of the head and neck, liver or breast, as reviewed (Kitareewan et al., 2002) . In contrast to these positive clinical trials, a recent intergroup randomized clinical chemoprevention trial of 13-cis retinoic acid (13cRA) was not beneficial in patients with previously resected stage I lung cancer, especially in active smokers (Lippman et al., 2001) . A potential benefit was observed in never smokers (Lippman et al., 2001) . This trial emphasizes the need to understand retinoid chemoprevention mechanisms linked to clinical response or resistance.
In vitro cell models are useful tools for retinoid chemoprevention studies. This study used an immortalized human bronchial epithelial cell line, BEAS-2B (Reddel et al., 1988) and the recently derived all-transretinoic acid (RA)-resistant BEAS-2B-R1 line (Dragnev et al., submitted) . BEAS-2B-R1 cells were derived as a single subclone from BEAS-2B cells after sequential passage in increasing RA dosages. BEAS-2B-R1 cells acquired resistance to RA-mediated growth inhibition (Dragnev et al., submitted) .
RA exerts its biological effects through nuclear retinoid receptors. The retinoic acid receptors (RAR) and retinoid X receptors (RXR) transcriptionally activate RA-target gene expression, as reviewed (Kitareewan et al., 2002) . RARb and RXRs play an important role in RA-induced growth suppression of human bronchial epithelial cells (Boyle et al., 1999) . Retinoid growth suppression was linked to cyclin proteolysis (Langenfeld et al., 1996; Langenfeld et al., 1997; Boyle et al., 1999) . Aberrant cyclin expression is frequent in bronchial preneoplasia . G1 arrest due to cyclin degradation was hypothesized to permit the repair of genomic DNA damage (Langenfeld et al., 1997) . Recent work revealed another retinoid chemoprevention mechanism involving transcriptional repression of the epidermal growth factor receptor (EGFR) during prevention of carcinogenic transformation of human bronchial epithelial cells (Lonardo et al., 2002) . Other potential retinoid chemopreventive mechanisms in bronchial epithelial cells include degradation of CDK-4 through the proteosomal pathway (Sueoka et al., 1999) and a decrease in the activity of telomerase reverse transcriptase (Soria et al., 2001) .
More needs to be learnt about the precise network of retinoid-mediated signals involved in cancer chemoprevention. Microarray analyses that can globally measure gene expression should enhance our understanding of chemopreventive pathways. Identification of RA-target genes that are differentially regulated in retinoidsensitive versus resistant cells could reveal specific pathways involved in RA response or resistance. These species might represent novel pharmacological targets or surrogate markers of retinoid clinical response. For these reasons, this study was undertaken to uncover RA targets linked to induced growth suppression of human bronchial epithelial cells.
Results
Two independent DNA microarrays were used to search for RA-regulated species in BEAS-2B human bronchial epithelial cells. Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) assays confirmed this regulation. BEAS-2B and RA-resistant BEAS-2B-R1 cells were each treated with RA or with the vehicle, dimethyl sulfoxide (DMSO). Differential expression of previously implicated or novel candidate RA-target genes was examined in these lines. Kinetics of RA induction was comprehensively analysed for highlighted species by RT-PCR assays, Western analyses or Northern analyses.
Gene expression profiles
Gene expression profiles were studied using Affymetrix Hu6800 and customized 8600 DNA microarrays, as described in the Materials and methods. There are 6095 and 7976 unique species displayed in these arrays, respectively, with 3002 overlapping species. RNA was harvested 24 h after RA treatment or treatment with the vehicle, DMSO. Although RA treatment would likely regulate the expression of species earlier than 24 h, this time point was selected for study since retinoid growth suppression was prominent at this time point in these cells (Langenfeld et al., 1997) . As compared to controls, 29 species in the 6800 array (0.48%) and 31 species in the 8600 array (0.39%) were induced at least twofold by RA treatment. In contrast, 18 species in the 6800 array (0.30%) and 34 species in the 8600 array (0.43%) were repressed at least twofold by 24 h after RA treatment in BEAS-2B cells. This study examined those species induced by RA treatment fourfold or greater and several that were induced between three-and fourfold. RT-PCR assays validated these findings (Figure 1) .
A total of 11 species were confirmed by RT-PCR assays as induced, including the inhibitor of DNA binding 1 (Id1), placental bone morphogenetic protein (PLAB), putative lymphocyte G0/G1 switch gene (G0S2), insulin-like growth-factor-binding protein 6 (IGFBP6), heme oxygenase 1 (HMOX1), tumor necrosis factor-a-induced protein 2 (TNFAIP2), polyamine oxidase isoform-1 (PAOh1), E74-like factor 3 (ELF3), FOSL1, ASNS and TGM2, as shown in Figure 1 . The fold changes of these regulated species are displayed in Table 1 . Of these species, nine appeared on both microarrays, while HMOX1 and PAOh1 were displayed only on the 6800 microarray (Table 1) . RA induced the expression of five species present on both microarrays. RA induction of these species was further confirmed by Northern or Western analyses as shown in Figures 2-5.
Expression of previously implicated RA-target genes RA induction of previously implicated RA target genes was compared in BEAS-2B cells and BEAS-2B-R1 cells ( Figure 2 and Table 2 ). Owing to technical limitations of Northern analysis for G0S2 expression and immunoblot assays for HMOX1 using a polyclonal anti-HMOX1 antibody in BEAS-2B cells, RT-PCR assays were performed for these species. Induction of G0S2 and HMOX1 mRNA expression was detected in RA-treated BEAS-2B cells by 7 h, but induction of G0S2 was blunted while HMOX1 induction did not occur in BEAS-2B-R1 cells ( Figure 2a and Table 2 ). Northern analyses confirmed induction of IGFBP6 and ASNS mRNA expression after 24 h of RA treatment ( Figure 2b and Table 2 ). Retinoid induction of IGFBP6 was similar in BEAS-2B and BEAS-2B-R1 cells while ASNS induction was absent in BEAS-2B-R1 cells, as depicted in Figure 2b and Table 2 . Immunoblot analyses confirmed that RA induced Id1, TNFAIP2, FOSL1 and TGM2 protein expression by 24-48 h ( Figure 2c and Table 2 ). Their induction was blunted after RA treatment of BEAS-2B-R1 cells ( Figure 2c and Table 2 ). The kinetics of retinoid induction of previously implicated target genes was studied in BEAS-2B cells. The findings in Figure 3 indicate that RA augmented G0S2, HMOX1 and IGFBP6 mRNA expression by 3 h. Basal ASNS mRNA expression was repressed by vehicle treatment (data not shown). RA induced ASNS by 7 h as compared to vehicle-treated controls (data not shown). TNFAIP2, Id1, FOSL1 and TGM2 protein expression was induced by 7 h of RA treatment ( Figure 3c ). Two Id1 species and multiple FOSL1 immunoreactive species were detected by immunoblot analyses (Figure 3c ). RA coordinately regulated these species, as shown in Figure 3c . These immonoreactive species might result from different post-translational modifications or alternatively spliced species.
Expression of novel candidate RA-target genes RA induction of novel RA-target genes was compared in BEAS-2B and BEAS2B-R1 cells ( Figure 4 and Table 2 ). RA induced PAOh1 mRNA expression by 24 h in BEAS-2B cells, but this induction was blunted in BEAS-2B-R1 cells, as depicted in Figure 4a and Table 2 .
Basal PLAB immunoblot expression was repressed in BEAS-2B-R1 cells as compared to BEAS-2B cells ( Figure 4b ). RA treatment markedly increased PLAB expression in BEAS-2B cells ( Figure 4b and Table 2 ). However, RA treatment of BEAS-2B-R1 cells only increased PLAB expression to levels similar to control BEAS-2B cells (Figure 4b ). Basal ELF3 mRNA expression was undetected in BEAS-2B or BEAS-2B-R1 cells (Figure 4c ). Unlike the kinetics observed for other RAregulated species in BEAS-2B versus BEAS-2B-R1 cells (data not shown), the change in the expression of ELF3 in BEAS-2B as compared to BEAS-2B-R1 cells was different. For this reason, the kinetics of the RA induction of ELF3 in BEAS-2B as compared to BEAS-2B-R1 cells is displayed in Figure 4c . BEAS-2B cells exhibited a maximal ELF3 induction at 3 h after RA treatment, while BEAS-2B-R1 cells had a delayed peak of this induction ( Figure 4c ). Two ELF3 species were coordinately regulated by RA treatment of BEAS-2B cells (Figure 4c ). The more abundant and faster migrating species was of the expected size for ELF3 mRNA. The signal from the slower migrating species might represent a preprocessed ELF3 transcript or crosshybridization to a homologous species. RA treatment induced mRNA expression of PAOh1 and ELF3 by 3 h and PLAB protein expression increased by 7 h as shown in Figures 4c and 5.
Discussion
To identify RA-target genes that play key roles in RAmediated growth suppression of human bronchial epithelial cells, microarray analyses were used. A total of 11 species that were induced at least threefold after 24 h RA treatment on the indicated arrays were independently confirmed as RA induced by RT-PCR assays, Northern or Western analyses. Eight were previously identified as retinoid regulated. These were G0S2 (Tamayo et al., 1999) , TNFAIP2 (Rusiniak et al., 2000) , Id1 (Toulouse et al., 2000) , FOSL1 (Kaiser et al., 1999) , TGM2 (Davies et al., 1985) , IGFBP6 (Gabbitas and Canalis, 1996) , HMOX1 (Kitamura et al., 1999) and ASNS (Hongo et al., 1990) . Three novel candidate RA-target genes were identified: PLAB, PAOh1 and ELF3. Thus, RA induced the expression of a limited set of mRNAs in human bronchial epithelial cells.
Among previously identified RA-regulated species, TGM2 (Zhang et al., 1995) and IGFBP6 (Sueoka et al., 2000a) were reported as retinoid induced in bronchial epithelial cells and Id1 (Toulouse et al., 2000) was induced by RARb transfection in lung cancer cells. RA regulated G0S2 (Tamayo et al., 1999) , TNFAIP2 (Rusiniak et al., 2000) and FOSL1 (Kaiser et al., 1999) expression in other cell types. RA treatment repressed ASNS in leukemic cell lines (Hongo et al., 1990) , but ASNS was induced by RA treatment of BEAS-2B cells, as shown in this study.
Direct RA-target genes have functional retinoid response elements in their promoters that permit retinoid receptors to associate and alter transcription. Functional retinoid response elements exist in the IGFBP6 and TGM2 promoters Yan et al., 1996) . RA induced the expression of these species in the absence of de novo protein synthesis (Gabbitas and Canalis, 1996; Ou et al., 2000) . IGFBP6 and TGM2 are likely direct RA targets. The rapid induction of IGFBP6 and TGM2 expression displayed in this study is consistent with their potential roles as direct RA targets in human bronchial epithelial cells. Although functional retinoid response elements in TNFAIP2, a PML-RARa target, have not been reported, RA regulates its expression via a transcriptional mechanism (Rusiniak et al., 2000) . G0S2, TNFAIP2, Id1, FOSL1 and HMOX1 and the novel candidate RA-target genes PLAB, PAOh1 and ELF3 were also rapidly induced by RA treatment of BEAS-2B cells. Whether these are direct RA targets in human bronchial epithelial cells is the subject of future work.
Several of these candidate RA targets have been implicated in regulating proliferation, differentiation, apoptosis or cell survival. Among previously implicated candidate RA-target genes, IGFBP6 exerted growth inhibitory (Ferry et al., 1999) and proapoptotic activities (Sueoka et al., 2000b) . Id1 functioned as a differentiation inhibitor (Benezra et al., 1990; Sun et al., 1991) Kim et al., 2002) . FOSL1, a Fos family member, functioned in osteoclast differentiation (Matsuo et al., 2000) . It lacks the transactivation domain that exists in other Fos family members that relates to transforming activities (Tulchinsky, 2000) . FOSL1 may function as a negative regulator of AP-1 (Kaiser et al., 1999) . TGM2 catalyzed the posttranslational modification of proteins via Ca þ þ -dependent crosslinking reactions, as reviewed (Chen and Mehta, 1999) . Crosslinking activity has been implicated in the regulation of proliferation, differentiation, apoptosis and other biological functions, as reviewed (Chen and Mehta, 1999) . The GTP-bound form of TGM2 can act as a classic G-protein (Chen and Mehta, 1999) . Recent work implicated TGM2 as a survival factor, which contrasts with its apoptotic function (Antonyak et al., 2001; Nanda et al., 2001) . ASNS and HMOX1 were stress-induced enzymes (Arfin et al., 1977; BarbosaTessmann et al., 1999a, b; Otterbein and Choi, 2000) . Their induction could indicate a cellular survival role. TNFAIP2 functioned in myeloid development (Rusiniak et al., 2000) and was induced by cytokines (Sarma et al., 1992) . G0S2 was cloned as putative G0/ G1 switch gene (Russell and Forsdyke, 1991) , but its precise function is not yet known.
Among the novel RA targets, ELF3 is a tissue-specific member of the ets transcription factor/oncogene family that can play a role in differentiation (Andreoli et al., 1997; Oettgen et al., 1997) and TGF-b-dependent growth suppression (Chang et al., 2000) . Polyamine oxidase (PAOh1) is involved in the polyamine catabolism pathway and could promote apoptosis (Ha et al., 1997) . PLAB is distantly related to the TGFb family (Yokoyama-Kobayashi et al., 1997). It may act as an autocrine regulator limiting inflammation (Bootcov et al., 1997) . PLAB can promote growth inhibition (Tan et al., 2000) and apoptosis (Li et al., 2000; Baek et al., 2001) . A network of retinoid regulated species may cooperate to signal biological effects.
DNA microarray is a powerful tool for analyzing global gene expression. Yet, limitations in this technology exist. Of nine induced species present in the studied arrays, only five were RA induced in both (Table 1) . Differences in hybridized sequences or algorithmic analysis could account for this. Some retinoid-induced species in these microarrays were not confirmed by other assays. False-positive results could result from nonspecific binding to contaminants in the RNA preparations (Clarke et al., 2001) or crosshybridization to homologous species (Freeman et al., 2000) . This points out the need to verify microarray results. Important RA-target genes may not have been displayed on these arrays. For example, RARb, a known RA-target gene (de The et al., 1990), was not present on either array.
Despite these limitations, candidate RA-target genes were identified in this study, including several previously unrecognized. RA treatment prevented carcinogenic transformation of cultured human bronchial epithelial cells (Langenfeld et al., 1996) . Yet, a 13cRA-randomized clinical trial did not reduce second cancers in patients with previously resected stage I lung cancers (Lippman et al., 2001) . A potential benefit was found in those who never smoked, indicating that negative interactions can exist in smokers treated with a chemopreventive agent. More needs to be learnt about the mechanisms responsible for retinoid response or resistance in lung carcinogenesis.
This study compared the expression of candidate RA-target genes in BEAS-2B and RA-resistant BEAS-2B-R1 cells. The expression of most candidate RA-target genes was dysregulated in BEAS-2B-R1 cells. RA treatment of BEAS-2B-R1 cells prevented induction of HMOX1 and ASNS. Other species were induced by RA treatment of BEAS-2B-R1 cells, but induction was either blunted or displayed different kinetics, as compared to parental BEAS-2B cells. This occurred for G0S2, Id1, TNFAIP2, FOSL1, TGM2, PLAB, PAOh1 and ELF3. In contrast, prominent RA induction of IGFBP6 still occurred in BEAS-2B-R1 cells.
Several mechanisms could contribute to this aberrant target gene expression. Induction of cytochrome P450, cellular retinoic-acid-binding proteins (CRABPs) or P-glycoprotein could affect intracellular stores of RA and confer RA resistance (Delva et al., 1993; Kizaki et al., 1996) . Our preliminary studies showed defects in RA induction of RARb in BEAS-2B-R1 cells (Petty et al., personal communication) . Deregulation of RARb could contribute to aberrant retinoid target gene expression. Future studies will explore the functional role in RA response of these candidate target genes in human epithelial cells. Since a single clone of RAresistant human bronchial epithelial cells (BEAS-2B-R1) exists, it would be important to evaluate the expression of target genes in other retinoid-resistant cells once these become available. RARb repression is frequent in the bronchial epithelium of smokers (Ayoub et al., 1999) . Methylation of RARb may confer silencing (Virmani et al., 2000) and contribute to negative clinical chemopreventive effects with classical retinoids. Combining a demethylation agent with a classical retinoid might overcome RARb repression and perhaps clinical retinoid resistance. Alternatively, a nonclassical retinoid might by-pass resistance to a classical retinoid. Consistent with this, a randomized trial with the RAR and RXR agonist 9-cis-RA (9cRA), but not 13cRA, significantly increased RARb expression in the bronchial biopsies of former smokers (Kurie et al., 2003) . This indicated a potential clinical chemopreventive benefit of 9cRA, a nonclassical retinoid. A nonclassical retinoid might activate critical downstream signals of retinoid response, such as cyclin proteolysis (Langenfeld et al., 1997; Boyle et al., 1999) or repression of EGFR (Lonardo et al., 2002) . This study highlighted candidate RA-target genes that could represent novel pharmacological targets in bronchial epithelial cells.
In summary, this study used DNA microarray analyses to identify candidate RA-target genes in human bronchial epithelial cells. Several highlighted species were implicated in prior work, while others have not been previously recognized. Expression of many of these candidate RA-target genes was dysregulated in RAresistant BEAS-2B-R1 cells. This highlighted their potential roles in mediating RA response in human bronchial epithelial cells. Further evidence for the importance of the novel candidate RA-target genes in lung carcinogenesis comes from preliminary findings that these are often expressed in non-small cell lung cancer cases (data not shown). Future work will determine as to which of the candidate RA targets identified in this study are essential for retinoid response or confer retinoid resistance in the bronchial epithelium.
Materials and methods

Human bronchial epithelial cells
Immortalized human bronchial epithelial BEAS-2B cells and RA-resistant BEAS-2B-R1 cells were each cultured in serumfree LHC-9 medium (Biofluids, Rockville, MD, USA) at 371C in a humidified atmosphere of 5% CO 2 , as described (Reddel et al., 1988) . BEAS-2B-R1 cells were derived as a single clone from BEAS-2B cells after selection in increasing RA dosages (Dragnev et al., submitted). Exponentially growing BEAS-2B or BEAS-2B-R1 cells were treated with RA at a dosage of 4 mm for various time periods or with the vehicle, DMSO, as a control.
Gene expression profiles
Total RNA was isolated after 24 h from RA-treated BEAS-2B cells or vehicle-treated cells using Trizol reagent (Life Technologies, Gaithersburg, MD, USA) and converted into cRNA according to the manufacturer's instructions (Affymetrix, Santa Clara, CA, USA). The Affymetrix Hu6800 microarray (derived from Unigene 18, GenBank and TIGR) and the customized 8600 microarray contain 6095 and 7976 unique species, respectively. In total, 11 069 distinct species were present on these microarrays. Probe arrays were hybridized, washed and scanned according to the manufacturer's instructions (Affymetrix, Santa Clara, CA, USA). Primary data were processed using Affymetrix Microarray Suite 4.0 software (Affymetrix, Santa Clara, CA, USA) to determine the average difference value and assess signal intensity for each probe set. These microarrays were normalized using the global scaling method recommended by Affymetrix (Santa Clara, CA, USA). These data were used to generate fold change. Those species induced by RA treatment fourfold or more and selected species induced threefold or more (as compared to controls) were further examined, as described below.
RT-PCR assays
Total cellular RNA was isolated from BEAS-2B or BEAS-2B-R1 cells using RNeasy s Protect Mini Kit (Qiagen, Valencia, CA, USA). Contaminating DNA was removed from these RNA aliquots using a DNA-freet kit (Ambion, Austin, TX, USA). The cDNA was synthesized from 3 or 5 mg total RNA using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). PCR was performed using Taq polymerase (Invitrogen, Carlsbad, CA, USA). The optimal PCR cycle number was determined. PCR products were resolved on a 1% agarose gel stained with Gelstar s nucleic acid gel stain (BioWhittaker Molecular Applications, Rockland, ME, USA) and analysed using Stormt (Molecular Dynamics, Sunnyvle, CA, USA) and ImageQuant Software (Amersham Biosciences Corp, Piscataway, NJ, USA). Expression levels for each gene were normalized to b-actin levels. Fold changes were calculated as relative to vehicle-treated controls. At least two independent RT-PCR assays were performed for each highlighted species. After washing and incubating with an appropriate secondary antibody, detection was carried out using the enhanced chemiluminescence system (Amersham Biosciences, Piscataway, NJ, USA). Gene expression was analysed using Personal Densitometer SI TM (Molecular Dynamics, Sunnyvale, CA, USA) and ImageQuant Software (Amersham Biosciences Corp., Piscataway, NJ, USA). Expression levels for each gene were normalized to actin levels. Fold changes were calculated as relative to vehicle-treated controls. At least two independent immunoblot experiments were performed for each indicated species. Individual primary antibodies used were rabbit polyclonal antibodies that recognized Id1, Fra1/FOSL1 or B94/TNFAIP2 or goat polyclonal antibodies that recognized PTGF-b/PLAB or actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a murine monoclonal antibody that recognized TGM2 (NeoMarkers, Fremont, CA, USA). Antimouse and anti-rabbit antisera were purchased (Amersham Biosciences, Piscataway, NJ, USA) as was the anti-goat antisera (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Northern analysis
In total, 10 mg of total RNA were fractionated on a 1% agarose-formaldehyde gel and then transferred onto a nylon membrane (Schleicher and Schuell Inc., Keene, NH, USA). Prehybridization and hybridization to radiolabeled cDNA probes were performed as previously described (Langenfeld et al., 1997) . The cDNA probes were for PAOh1 (1.5 kb KpnI fragment of clone 4751227), ELF3 (819 bp EcoRI/XhoI fragment of clone 4777093), IGFBP6 (853 bp EcoRI/NcoI fragment of clone 4752593), ASNS (1.5 kb EcoRI fragment of clone 593052) or b-actin (Clontech, Palo Alto, CA, USA). Filters were optimally washed for each probe before exposure to a PhosphorImager screen with images analysed using Stormt (Molecular Dynamics, Sunnyvle, CA, USA) and ImageQuant Software (Amersham Biosciences Corp, Piscataway NJ, USA). Expression levels for each gene were normalized to b-actin levels. Fold changes were calculated as relative to vehicle-treated controls. At least two independent experiments were performed to examine the expression of each species.
